There were no sequence effects between two formulations in these parameters. The 90% confidence intervals for the log transformed data were acceptance range of log0.8 to log1.25 (e.g., log1.02 ~ log1.14 and log1.03 ~ log1.19 for AUCt and Cmax, respectively). The major parameters, AUCt and Cmax, met the criteria of KFDA for bioequivalence indicating that Enalace™ tablet is bioequivalent to Renitec™ tablet.

[PE2-18] [ 2003-10-11 09:00 - 12:30 / Grand Ballroom Pre-function ]

Pharmacokinetics of DA-8159, a new PDE5 inhibitor, after single and 1-week repeated oral administrations in mice


Dong-A Pharmaceutical Co. LTD., 47-5, Sanggal-ri, Kiheung-up, Yongin-si, Kyunggi-do, 449-905, Korea

DA-8159 is a new PDEV (Phosphodiesterase V) inhibitor, synthesized by Dong-A Pharm., as an oral agent to treat male erectile dysfunction. To make a selection of the dosage of oral administration in carcinogenic studies, we studied preliminarily the pharmacokinetics of DA-8159 after single (at the 1st day) and 1-week (at the 7th day) oral administrations of the drug at doses of 15, 50 and 150 mg/kg/day, to male ICR mice. In 15mg/kg single and 1-week repeated oral administration groups, the concentrations of DA-8159 and DA-8164 of the main metabolite of DA-8159 were below the limit of quantitation (LOQ: 50ng/ml). The AUC of DA-8159 was not significantly different between single and 1-week oral administration at 50mg/kg/day. But the AUC of DA-8159 150mg/kg/day 1-week oral administration group was two times higher than that of single administration group. The metabolic ratios (AUC of DA-8164 divided by AUC of DA-8159) of 1-week oral administration at 50mg/kg/day and 150mg/kg/day were increased than those of single oral administration groups. And the metabolic ratios of DA-8159 in mice were very high (over 100%). The metabolic ratio from DA-8159 to DA-8164 of mice was more than those of rats (48.9%), dogs (10.0%) and humans (59.4%).

[PE2-19] [ 2003-10-11 09:00 - 12:30 / Grand Ballroom Pre-function ]

Determination of Prazosin in Human Plasma Using a Validated HPLC Method and Bioavailability of a Tablet Formulation

Oh JungHyun*, Cho YoungAh, Gwak HyeSun, Noh EunSun, Lee NaYoung, Chun InKoo
Chosun University, College of Pharmacy, Dongduk Women’s University, College of Pharmacy

A rapid and reproducible high performance liquid chromatographic assay of prazosin in human plasma was developed. After addition of internal standard (IS, terazosin hydrochloride) and alkalization of the plasma, the drug and IS were extracted into t-butylmethylether. The organic phase was back-extracted with 0.05% phosphoric acid and 50 μl of the acid solution was injected into a reverse-phase C18 column with a mobile phase consisting of water : acetonitrile : triethylamine = 75 : 25 : 0.1 (pH 5.0). The samples were detected utilizing a fluorescence detector. Prazosin and IS showed good resolutions and an excellent linear relationship was (r² = 1) was obtained between the peak area ratios and the corresponding concentrations in the ranges of 0.5-50 ng/ml. The applicability of the method was demonstrated by analysis of plasma after oral administration of a single 2-mg dose to 16 healthy subjects. From the plasma prazosin concentration vs. time curves, the mean AUC0-12h was 108.4 ± 74.2 ng · h/ml and Cmax of 23.1 ng/ml reached 2.1 h after administration. The mean biological half-life of prazosin was 2.5 ± 0.6 h. (This study was supported by a grant from Korea Food and Drug Administration; KFDA-03142-EQI-519)

[PE2-20] [ 2003-10-11 09:00 - 12:30 / Grand Ballroom Pre-function ]

The Effect of Quercetin on the Pharmacokinetics of Paclitaxel in Rats

Choi Jun Shik*, Li Xiuguo
College of Pharmacy, Chosun University, Guangju 501-759, Korea

The purpose of this study was to investigate the effect of quercetin(2.0, 10, 20 mg/kg; combined or pretreated) on the
pharmacokinetic parameters and the bioavailability of paclitaxel (50 mg/kg) orally in rats. The plasma concentration of paclitaxel pretreated with quercetin (pretreated group) were increased significantly (p<0.01) compared to that of control, but those of paclitaxel combined with quercetin (combined group) were not affected. Area under the plasma concentration-time curve (AUC) of paclitaxel pretreated with quercetin was significantly (p<0.01) higher than that of control. Peak concentration (Cmax) of paclitaxel pretreated with quercetin were significantly increased (p<0.01) compared to that of control. Time to peak concentration (Tmax) of paclitaxel pretreated with quercetin decreased significantly (p<0.05) than that of control. Half-life (t1/2) of paclitaxel pretreated with quercetin was significantly prolonged (p<0.05) compared to that of control. Based on these results, it might be concluded that quercetin may enhance bioavailability of paclitaxel due to the inhibition of cytochrome P450 and P-glycoprotein, which are engaged in paclitaxel absorption and metabolism in liver and gastroduodenal mucosa, respectively.

[PE2-21] [2003-10-11 09:00 - 12:30 / Grand Ballroom Pre-function]

Bioequivalence of Two Enalapril Maleate Tablets (Enalapril maleate 20 mg)

Lee Sun-Young, Kim Dong-chool
ibiopharm Co., Ltd. Research Laboratory #307 Expetol, 381 Mannyon-dong, Suh-ku, Taejon, South Korea, College of Pharmacy, Chungnam National University, 220 Gung-dong, Yusung-ku, Taejon, South Korea

Bioequivalence of two enalapril maleate tablets, formulation A and B, was evaluated according to the Korean Guidelines for Bioequivalence Test (KGBT 2001). Twenty healthy male volunteers (19-27 years old) were randomly divided into two groups and a randomized 2x2 cross-over study was performed. Following oral administration of enalapril maleate tablets (20 mg dose), blood sample was taken at pre-determined time intervals and the concentrations of enalapril in plasma were determined using LC-MS. A statistical difference of bioavailability parameters (AUClast, Cmax, and Tmax) between the two formulations was tested by ANOVA (EquivTest ver 2.0, Statistical Solutions Ltd.). The result showed that the differences in AUClast, Cmax, and Tmax between the two formulations were 3.36%, 0.44%, and -1.11%, respectively. Ninety percent confidence intervals of Log(AUClast) and Log(Cmax) were 0.9829-1.2002 and 0.9491-1.1237, respectively.

[PE2-22] [2003-10-11 09:00 - 12:30 / Grand Ballroom Pre-function]

Plasma Pharmacokinetics and Urinary Excretion of Isoflavones After Ingestion of Soy Products with Different Ratio of Aglycone/Glucoside in Korean women

Chang Youngguin, Choue Ryowon, Kim Chungsook
Department of Medical Nutrition, Graduate School of East-West Medical Science, Kyung Hee University, Seoul, Korea, Drug Research and Development Team, Korea Institute of Oriental Medicine, Seoul, Korea

Lately, soybeans have received considerable public attention for their potential roles in the prevention of the chronic diseases. Epidemiologic study showed that Asian countries have significant health benefits because of the high contents of the isoflavones in their traditional diets (soybean-rich diet). This study was carried out to determine pharmacokinetic parameters of isoflavone in Korean woman. Pharmacokinetic study of three soy products (isogen, soymilk, and fermented soybean) with different ratio of aglycone/glucoside in 26 healthy female volunteers (20-30 years of age) was performed. After ingestion of three soy products, the plasma and urine concentrations of isoflavones were measured by HPLC. The pharmacokinetic parameters were estimated using the WinNonlin program. The plasma AUC of daidzein in soymilk (210±352 μg/hr/L) ingested group was significantly lower than those of isogen (262±573 μg/hr/L) and fermented soybean (2593±465 μg/hr/L) ingested group. The plasma Cmax of daidzein in soymilk (231±44ng/ml) ingested group was significantly higher than those of isogen (160±32ng/ml) and fermented soybean (195±35ng/ml) ingested group. The half-life of daidzein and genistein in soymilk ingested group (5.9h and 5.6h respectively) was significantly shorter than those of isogen (9.6h and 8.5h respectively) and fermented soybean (9.5h and 8.2h respectively) ingested group. The urinary recovery of daidzein and genistein were 42% and 17% in isogen ingested group, 46% and 23% in fermented soybean ingested group, and 33% and 22% in soymilk ingested group. In conclusion, soy products containing high aglycone forms of isoflavone are more effective than soy products containing low isoflavone.